Initiation of Anticoagulation in Atrial Fibrillation
Anticoagulation should be started in patients with non‑valvular atrial fibrillation when the CHA₂DS₂‑VASc score denotes elevated thrombo‑embolic risk. Direct oral anticoagulants (DOACs) are preferred over warfarin as first‑line therapy. [1][2][3]
Risk Stratification
- Men: initiate anticoagulation when CHA₂DS₂‑VASc ≥ 2.
- Women: initiate anticoagulation when CHA₂DS₂‑VASc ≥ 3.
These thresholds define “high‑risk” AF as used in contemporary guideline recommendations. [1][2]
Preferred Anticoagulant Class
- DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are recommended as first‑line agents for eligible patients.
- Warfarin is reserved for patients with contraindications to DOACs or with mechanical heart valves.
Guideline statements endorse DOACs as the primary option for non‑valvular AF. [2][3]
Assessment of Bleeding Risk
- Calculate the ATRIA or HAS‑BLED score to gauge bleeding risk before initiating therapy.
- High bleeding risk does not automatically preclude anticoagulation; shared decision‑making and mitigation strategies are advised.
The cited rural cohort study incorporated ATRIA bleeding scores in its evaluation of anticoagulation use. [1]
Implementation Considerations
- Initiate therapy promptly after confirming the CHA₂DS₂‑VASc threshold is met.
- Counsel patients on adherence, renal function monitoring, and drug‑drug interactions.
- Re‑evaluate stroke and bleeding risk annually or after clinical changes.
Guideline recommendations emphasize early initiation and ongoing risk reassessment. [2][3]